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Abstract
Bone marrow has already been described as an enrichment site for several antigen-
specific T lymphocytes, but the presence of mould-specific T cells has never been inves-
tigated in the bone marrow. We have previously demonstrated that mould-specific T cells
emerge in the peripheral blood of patients with invasive fungal infections (IFI) but tend to
become undetectable after disease resolution. In seven patients with a history of IFI, we
investigated the presence of mould-specific T cells secreting different cytokines in bone
marrow and peripheral blood paired samples. The results showed that the frequencies
of mould-specific T cells secreting the protective cytokine IFNγ are significantly higher in
bone marrow (BM) and are mainly represented by CD8+ T lymphocytes with effector phe-
notype. A putative disappearance of such protective BM responses after myeloablative
therapy could contribute to the increased risk of IFI in hematologic patients.
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Introduction
Invasive mould infections (IMI), mainly invasive aspergillo-
sis (IA) and invasive mucormycosis (IM), remain a ma-
jor cause of morbidity and mortality in patients with
hematologic malignancies, in particular for acute leukemia
patients and hematopoietic stem cell transplant (HSCT)
recipients.1 We previously demonstrated that, during the
course of either IA or IM, mould-specific T cells may emerge
in the peripheral blood (PB) of hematologic patients.2–4
The detection of specific T cells against filamentous fungi
in patients’ PB not only represents an alternative diagnos-
tic marker of IMI5 but also seems to correlate with disease
course. However, these mould-specific T cells tend to be-
come undetectable in the PB after disease resolution.3,4
Different antigen-specific T cells have already been
described to reside preferentially in the bone marrow
(BM), namely, virus-specific6–8 or tumor-specific T lym-
phocytes.9–13 To address the hypothesis that BM could be
a site of enrichment also for mould-specific T cells, we an-
alyzed frequencies and phenotypes of mould-specific T-cell
responses in paired BM and PB samples of hematologic
patients with an history of IMI.
Material and methods
Patients
We studied a cohort of seven hematologic patients, who
have developed IMI. According to EORTC/OMSG crite-
ria,14 four cases were classified as proven disease, namely,
three IA and one IM, while the remaining three patients
were classified as probable IA. Patients’ clinical features are
summarized in Table 1. Basal immunophenotypic analyses
to assess absolute T-cell counts were routinely performed
for clinical scope, during patients’ follow-up. Paired sam-
ples of BM and PB were serially collected after IMI diagno-
sis (range 3–42 months) in order to perform mould-specific
cytokine capture assays. Of note, in these sample series,
median ratios of CD4/CD8 in BM (1.8 ± 0.7) and in PB
(2.9 ± 1.3) were in line with normal values previously re-
ported.8,15 Written informed consents were obtained in ac-
cordance with the Declaration of Helsinki, after the local
Ethical Committee’s study approval (protocol no. 2414–
63/11).
Methods
BM and PB mononuclear cells (BMMCs and PBMCs, re-
spectively) were isolated by standard density gradient sepa-
ration. The presence of mould-specific T cells was assessed
by using the cytokine secretion assay (CSA) for different
cytokines: interferon gamma (IFNγ ), tumor necrosis factor
alpha (TNFα), interleukin 10 (IL10), interleukin 4 (IL4),
and interleukin 17A (IL17A). All experiments were con-
ducted in triplicate according to the manufacturer’s in-
structions, with few modifications, as already reported.3,4
Briefly, 1 × 106 PBMCs or 1 × 106 BMMCs were stim-
ulated with germinated and heat inactivated conidia, at a
final concentrations of 100,000–200,000/ml, for 17 hours
(IFNγ , TNFα and IL4 assays) or 40 hours (IL10 and IL17A
assays). Aspergillus conidia or sonicated Mucorales conidia
were used to detect reactive T cells in patients with either
IA or IM, respectively. Unstimulated and PHA-stimulated
PBMCs/BMMCs were used as negative and positive con-
trols, respectively. Cells were acquired on a FACSCalibur
flow cytometer and analyzed by using CellQuest and Sum-
mit softwares. The phenotype of the cytokine-producing
cells was directly assessed after sample counterstaining with
monoclonal antibodies directed to CD3 and to CD8 or
CD4, and to the lymph node homing receptor CD62L (also
CCR7 was used instead of CD62L in duplicated experi-
ments). In addition, the cytotoxic phenotype of CD8+ or
CD4+ T cells was assessed by using a monoclonal antibody
against the degranulation marker CD107a.13 The gating
strategy is described in Supplementary Information S1 (Fig-
ure S1). Percentages of mould-specific cytokine+ T cells
(out of either CD8+ or CD4+ T lymphocytes) were cal-
culated as mean differences compared with unstimulated
controls. In addition, the absolute frequencies of mould-
specific IFNγ -secreting T cells were directly calculated
from absolute counts of CD3+ CD8+ or CD3+ CD4+
cells (performed in parallel by using BD TruCOUNTTM
tubes).
Statistical analysis
Statistical analysis were conducted using a Wilcoxon signed
rank test to derive P values for comparing data between
paired PB and BM samples; P values less than .05 were
considered statistically significant.
Results
CSA analysis revealed the presence of mould-specific
cytokine+ T cells in all the analyzed samples from all seven
patients. At a median time of 12 months after IMI diagno-
sis (range 3–33), mean frequencies of these conidia-reactive
T lymphocytes were generally higher in BM than in PB.
Mean frequencies (percentage ± standard deviation) in BM,
compared with PB, resulted as follows: IFNγ -producing
T cells (3.24% ± 6.10 vs 0.67% ± 1.24), TNFα-producing
T cells (0.43% ± 0.59 vs 0.37% ± 0.64), IL10-producing T
cells (0.22% ± 0.33 vs negative), IL17A-producing T cells
(0.16% ± 0.18 vs 0.15% ± 0.23) and IL4-producing T cells
(0.59% ± 0.63 vs 1.27% ± 1.35) (Figure 1A). Of note,
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Table 1. Patients’ clinical features.
Patient Sex/Age Underlying disorder Site of Analyzed samples
no. (yr) or condition Infection Isolates/biopsy Galactomannan (months after IMI diagnosis)
1 F/27 AML Lung/maxillary sinus IA proven pos 3
2 F/59 AML Lung IA proven pos 8;12;24
3 F/40 AML Lung IA proven neg 9;12;24
4 M/72 AML Lung Aspergillus spp/
IA probable pos 4;6
5 F/47 AlloSCT Lung -/IA probable pos 6;12;24
6 F/61 AlloSCT Lung -/IA probable pos 12;24
7 M/40 AML Left cavernous sinus IM proven neg 24;33;42
Note: F = female; M = male; AML = acute myeloid leukemia; AlloSCT = allogeneic stem cell transplant; IA = invasive aspergilosis; IM = invasive mucormycosis;
pos = positive; neg = negative; IMI = invasive mould infection.
Figure 1. Characterization of mould-specific T cells in 7 patients with history of Invasive Mould Infection (IMI), by performing Cytokine Secretion
Assays (CSA) on paired bone marrow (BM) and peripheral blood (PB) samples collected at median time of 12 months after IMI diagnosis. (A)
Frequencies of mould-specific T cells secreting IFNγ , TNFα, IL10, IL17A or IL4, in BM and PB samples. Results are expressed as mean percentages of
CD8+ T cells (white columns) or CD4+ T cells (gray columns). Magnitudes of specific cytokine+ T cells for individual time points are also reported
in each columns (white circles). All patients showed higher proportions of mould-specific T cells in the BM compared to PB. Concerning to IFNγ -
producing T cells, differences between BM and PB were statistically significant (P = .0051), as well as differences between CD8+ and CD4+ in the
BM (P = 0.0125). ∗P < .05, Wilcoxon signed rank test. (B) Expression profiles of the homing lymphocyte receptor CD62L in mould-specific BM T-cell
repertoire. For each cytokine+ mould-specific T-cell subset, white portions represent the mean percentages of CD8+ CD62L- T cells, black portions
represent the mean percentages of CD8+ CD62L+ T cells, light gray portions represent the mean percentages of CD4+ CD62L- T cells, dark gray
portions represent the mean percentages of mold-specific CD4+ CD62L+ T cells.
and PB were statistically significant (P = .0051). Moreover,
among these specific IFNγ -secreting BM T lymphocytes, the
fraction of CD8+ T cells (2.65% ± 5.73) was significantly
higher than CD4+ T cells (0.59% ± 0.45) (P = .0125).
The analysis of CD62L expression among mould-specific
cytokine+ BM T cells is reported in Figure 1B. Concerning
to IFNγ -producing subsets, we observed that both CD8+
and CD4+ were skewed to a CD62L- effector phenotype
(CD62L-/CD62L+ ratios were 1.42 and 1.18 in CD8+ or
CD4+ T-cell subsets, respectively).
In 4 out of 7 patients, we had the possibility to longi-
tudinally collect and test some further paired BM and PB
samples, collected at a median time of 27 months after IMI
diagnosis (range 24–42), aiming to investigate whether such
protective BM immune responses may (i) persist after long
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Figure 2. Characterization of IFNγ -producing mould-specific T cells in 4 out of 7 patients with history of IMI, by performing CSA analyses on paired
BM and PB samples collected at median time of 27 months after IMI diagnosis. (A) The expression of CD62L among IFNγ -secreting mould-specific T
cells in BM and PB samples is shown as mean percentage of CD62L- T cells (white columns) and CD62L+ T cells (gray columns), within either CD8+
or CD4+ T-cell subsets. In addition, magnitudes of single data points are depicted as CD62L- (white circles) and CD62L+ (gray circles). CSA analyses
confirmed that mould-specific IFNγ -producing T cells were still prevalently enriched in the BM and that IFNγ was produced more frequently by CD8+
T cells than by CD4+ T cells (P = 0.025). ∗P < .05, Wilcoxon signed rank test. (B) The expression of the degranulation marker CD107a shows relevant
proportions of CD8+ and CD4+ mould-specific IFNγ -producing BM T cells with potential cytotoxic activity, similar to what observed in PB samples.
Gray and white columns represent the mean percentages of CD107a+ and CD107a-, respectively, within either CD8+ or CD4+ T-cell subsets, in
BM and PB samples. In addition, magnitudes of single data points are depicted as CD107a+ (gray triangles) and CD1047a+ (white triangles). (C)
Comparison of absolute numbers of IFNγ -producing mould-specific T cells over time, for the 4 patients with 3 time points analyzed. Gray and white
diamonds represent data from BM and PB samples, respectively.
CD62L expression, and (iii) reveal cytotoxic potentials. In-
deed, in this second set of experiments, we were able to
confirm that mould-specific IFNγ -producing T cells were
still prevalently enriched in the BM (BM 1.59% ± 1.3 vs
PB 0.34% ± 0.16, P = .017) and that IFNγ was produced
more frequently by CD8+ T cells (1.02% ± 0.84) than
by CD4+ T cells (0.57% ± 0.46), in a statistical manner
(P = .025) (Figure 2A). This consistent BM enrichment was
also evident after calculation of the absolute numbers of BM
and PB conidia-reactive IFNγ+ T cells over time (shown in
Figure 2C).
When considering CD62L expression profiles among
these long-lasting BM T lymphocytes, we observed that
CD4+ T cells switched to a prevalent CD62L+ pheno-
type (CD62L-/CD62L+ ratio = 0.73), while CD8+ T cells
did not show a relevant modification (CD62L-/CD62L+
ratio = 1.44) (Figure 2A). Furthermore, with regard to the
surface expression of the degranulation marker CD107a,
mould-specific IFNγ -producing BM T cells showed relevant
proportions of CD8+ (mean 0.69% ± 0.79) and CD4+
(mean 0.44% ± 0.36) T cells with potential cytotoxic ac-
tivity, similar to what observed in PB samples (Figure 2B).
Discussion
To our knowledge, this is the first report showing the pres-
ence of T-cell immune responses against filamentous fungi
in the BM. We serially performed CSA immunoassays for
different cytokines to identify and functionally character-
ize mould-specific CD8+ and CD4+ T cells in paired BM
and PB samples, longitudinally collected from a series of
leukemic patients, who developed IMI (either IA or IM)
during induction chemotherapy or after HSCT. Here we
demonstrated that 7 out of 7 patients (100%) showed sig-
nificantly higher proportions of mould-specific T cells in the
BM, compared with the PB. In particular, these specific BM
immune responses were characterized by high frequencies
of protective IFNγ -producing T cells, which still remained
detectable several months after IFI complete regression.
These data evidenced that BM may play a pivotal role
as a reservoir of mould-specific T cells in patients with a
history of either IA or IM. This finding is in line with
previous immunologic reports, which have described the
BM as a relevant enrichment site for memory T lympho-
cytes,16 against hematologic malignancies9,11–12 and solid
tumors,10,13 as well as against different human viruses.6–8
Of note, we showed that mould-specific IFNγ -producing
BM T cells were mainly “effector” CD62L- CD8+ T-cells,
and this resembles the prevalent protective BM T-cell sub-
set with a memory role against WT1,13 BCR-ABL1,11–12
EBV6–7 or CMV6,9 antigens. Moreover, we observed a late
switch toward “central” CD62L+ CD4+ IFNγ+ T cells,
while no relevant changes occurred among CD8+ subsets.
This late profile of mould-specific T cells is similar to the
mixed patterns of effector memory (EM) CD8+ and central
memory (CM) CD4+ specific T cells, detected in the BM of
EBV+ healthy subjects7 and in the BM of leukemic patients
controlling the disease.11–12 However, with our experimen-
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subset within the pool of responding T cells was constituted
by CD62L+ (CD45RA+) naive T cells.17
Furthermore, similarly to what reported for tumor-
specific and virus-specific immune responses,7,13 we also
demonstrated the cytotoxic potentials of mould-specific
IFNγ -producing BM T lymphocytes. At the opposite of
mould-reactive IFNγ -secreting T lymphocytes, the frequen-
cies of specific IL4+ T cells were markedly higher (even if
not in a statistical manner) in the PB rather than in the
BM. This observation is consistent with the “suppressive”
role of IL4-producing Th2 cells, as well as with the notion
about the plasticity of functional T-cell subsets, suggesting
that Th1 memory cells may also co-express IFNγ and IL-4
to control secondary immune responses.18,19
Interestingly, Okhrimenko et al.,8 suggested that, in
healthy subjects, the BM is not the preferred site of hom-
ing for CD4+ memory T cells against Candida albicans
(MP65 antigen), possibly because Candida is a nonfila-
mentous fungus (yeast) typically affecting skin and mucosa
in immunocompetent patients. Our survey has shown for
the first time that, against filamentous fungi, long-lasting
immune responses (mainly constituted by specific IFNγ -
producing T lymphocytes) are markedly enriched in the
BM of hematologic patients who previously developed an-
gioinvasive fungal diseases. Additional analyses are war-
ranted to describe functional EM/CM T-cell subsets within
mould-specific BM repertoire, including double-cytokine+
subsets and different specificities to conidia-derived
antigens.
In conclusion, a likely scenario is that long-term IFNγ -
producing (“protective”) T cells against moulds may pref-
erentially rest in the BM and move to the PB in response
to antigenic rechallenges. Intensive cytotoxic chemotherapy
(i.e., myeloablative CHT, used as conditioning treatment
for HSCT and as induction therapy for acute leukemias) is
typically able to eliminate the majority of T cells residing
in the BM. Thus, it is possible to speculate that the impair-
ment of these mould-reactive BM T lymphocytes due to
myeloablative CHT could represent a relevant factor con-
tributing to the increased risk of IMI in HSCT and acute
leukemia patients. Further studies are required to investi-
gate whether such anti-fungal immune reservoir in the BM
may have an essential protective role in the prevention of
IMI. In perspective, BM may be exploited as a source for
expansion of Aspergillus-specific and Mucorales-specific T
cells, in order to plan adoptive therapeutic strategies in IMI
patients candidate to HSCT.
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